An expert panel of India's Central Drug Authority recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on children aged 2 to 17 years
This comes as the court said it would be a "disaster" if Covid-19 vaccines are administered, especially to children, without clinical trials
Clinical trial shows molnupiravir helps in early recovery in non-hospitalised Covid-19 patients
The phase-2 trials of the locally developed vaccine against Covid-19 started to be administered to volunteers in Istanbul, local media reported
The agency said the suspension - which put the EUA application on ice - was due to missing data from the vaccine's clinical trials
The company claimed Covaxin is the first to report promising efficacy against asymptomatic infections based on qPCR testing that will help in reducing disease transmission
The recruitment for the clinical trial of the country's first indigenously-developed COVID-19 vaccine, Covaxin, among children in the age group of 6-12 years will begin at the AIIMS here from Tuesday. This will be followed by the clinical trial of children in the age-group of 2-6 years. The enrolment of children volunteers aged 12-18 years at the All India Institute of Medical Sciences (AIIMS) has been completed and they have been given the first dose of Covaxin. "The recruitment process for the clinical trial of Covaxin among children in the age group of 6-12 years will begin from Tuesday," Dr Sanjay Rai, Professor at the Centre for Community Medicine at the AIIMS, told PTI. The Drugs Controller General of India (DCGI) had granted permission for conducting the phase 2/3 clinical trial of Bharat Biotech's Covaxin among children aged two to 18 years on May 12. The trial is to be conducted in three parts -- 175 volunteers each in the groups aged 12-18, 6-12 and 2-6 years. In the tr
On track to make 100 mn doses per month by Q3 of 2021
Council of Scientific and Industrial Research (CSIR) along and Laxai Life Sciences Pvt. Ltd. on Sunday initiated Phase-II clinical trial for anti-helminitic drug Niclosamide for treatment of Covid-19.
Company says product helps treating mild coronavirus patients and reduces hospitalisation.
The clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August.
India's apex drug regulator has granted permission for conducting the phase II/III clinical trial of Bharat Biotech's Covaxin Covid-19 vaccine in the age group of 2 to 18 years
Bharat Biotech's Covid-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said
Says the company would like to recover the costs incurred in clinical trials, and other things and reinvest the money into R&D to be ready for future pandemics
Gennova's Covid vaccine candidate HGCO19 would remain stable at 2 to 8 degree Celsius temperature
Expert panel recommends emergency use authorisation
Singapore-based cyber intelligent firm Cyfirma says 15 active hacking campaigns are underway; US, UK and Japan among a slew of other nations also on cybercriminals' target list
Progressive Medicos and Scientists Forum said the Clinical Trial (PMSF) Phase 3 data should be evaluated in a transparent manner as and when available for India for both vaccines
More than 5,000 people have been given both shots of the vaccine; efficacy data around March
Other vaccines being developed in India, dangerous conspiracy theories, private hospitals keen on jumping in-news relevant to India's fight against Covid-19